Login & Signup

  • PreIPO
  • Startup Fund Raising
  • Valuations
  • Equity Restructing

  • Investments
  • Mutual Funds
  • Demat Account
  • Bonds/NCD
  • Insurance
  • Life Insurance
  • Health Insurance
  • Car Insurance
  • Corporates & Business
  • Property Insurance
  • Group Health Insurance
  • Marine Insurance

Snapshot
Key Ratio
Peers
Financials
Ownership
News
Events

RATING

RECOMMENDATION

Strong Buy

  • Portfolio

  • Basket

  • Watchlist

  • More

Snapshot
Key Ratio
Peers
Financials
Ownership
News
Events

RATING

RECOMMENDATION

Strong Buy

Business Type

Emerging Leader

  • Martin & Harris Unlisted Shares Essentials

Discover and get complete analysis on Martin & Harris Laboratories upcoming IPO unlisted shares - Management, Business Model, Financials, Growth, Valuations, Funding Rounds, News and latest updates.

ISIN

INE03VV01015

Face Value

₹10.00

Total Share

39,96,040

Total Income

₹296.67 Crores

Profit After Tax

₹69.11 Crores

EPS

₹172.96

Book Value

₹278.45 Crores

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Upcoming IPO

Cashflow - Operations

₹10.13 Crores

Cashflow - Financing

₹32.87 Crores

Martin & Harris Growth

Compounded Sales Growth

  • 2.34%

    1 Year

  • 29.33%

    2 Year

  • 29.35%

    3 Year

Pro Only

Compounded Profit Growth

  • -4.60%

    1 Year

  • 7.86%

    2 Year

  • 33.62%

    3 Year

Pro Only

Return On Equity

  • 23.63%

    1 Year

  • 32.92%

    2 Year

  • 38.99%

    3 Year

Pro Only

About Martin & Harris

  • Martin & Harris Laboratories Ltd incorporated in 1996 at Gurgaon, Haryana is a part of “Apeejay Group”, India’s oldest and largest business conglomerates.
  • Martin & Harris Laboratories Ltd is engaged in the manufacturing of Pharmaceutical, medicinal chemical & botanical products. Besides the core business, it has undertaken the management of its funds through investment in different avenues fetching good returns i.e., mutual funds, equity –quoted & unquoted, etc.
  • The company has its units located at Roorkee and UNA Himachal Pradesh
  • Its authorized share capital is ₹ 500,000 and its paid-up capital is ₹ 207,600.
  • Martin & Harris is majorly in the manufacturing (Metals & Chemicals, and products thereof) business for the last 41 years and currently, company operations are active.

  • Martin & Harris Product & Services

Pharmaceutical Products
Bulk Drugs
Medicine (Allopathic)
Clopidogrel
Nicorandil
Losartan Potassium
Metoprolol Tartrate

  • Martin & Harris Industry Overview

Industry Statistics

  • In FY2020, the pharmaceutical sales grew 9% y-o-y to ₹ 10,342 Cr. India contributes the second-largest share of the pharmaceutical and biotech workforce in the world. In FY2020, the pharmaceutical sales grew 9% y-o-y to ₹ 10,342 Cr. India contributes the second largest share of the pharmaceutical and biotech workforce in the world.
  • Indian pharmaceutical sector supplies over 50% of the global demand for various vaccines, 40% of the generic demand for the US, and 25% of all medicines for the UK.
  • During December 2019, on a moving annual total (MAT) basis, industry growth was at 9.8%, with price growth at 5.3%, new product growth at 2.7%, while volume growth at 2% y-o-y.
  • Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medical spending.
  • India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected to grow at an average growth rate of around 30% a y-o-y
  • to reach ₹ 7,24,800 Cr by 2025.
  • Indian pharmaceutical sector is expected to grow to ₹ 7,24,800 Cr, while the medical device market is expected to grow by ₹ 1,81,200 in 2025. Pharmaceuticals exports from India stood at ₹1,500,54 Cr in FY20. Pharmaceutical export includes bulk drugs,
  • intermediates, drug formulations, biologicals, Ayush and herbal products and surgical.

Government Initiatives

  • Pharma Vision 2020’ by the Government’s Department of Pharmaceuticals aims to make India a major hub for end-to-end drug discovery. The sector received cumulative Foreign Direct Investment (FDI) worth ₹ 1,19,898 Cr between April 2000 and June 2020.
  • Under Union budget 2020-21, allocation to the Ministry of Health and Family Welfare stands at ₹ 65,012 crores, whereas, ₹ 6,429 crores have been allocated to the health insurance scheme, Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (ABPMJAY).

Martin & Harris Strengths

  • Martin & Harris enjoys a High EBITDA & PAT margin compared to its listed peers.
  • Martin & Harris also depicts high CAGR growth in total income compared to peers over the period of 4 years.
  • Debt/ Equity ratio is the lowest and the Asset Turnover ratio is higher compared to peers. 
  • The company’s EBITDA has been increasing at a CAGR of 30.9% from 2017 to 2020.
  • Martin & Harris Laboratories Ltd. has a higher ROCE Ratio. The company’s ROCE Ratio is 34.2% if compared to Industry Average ROCE is 21.4%.
  • The company’s Operating profit has been increasing at a CAGR of 30.2% from 2017 to 2020.

Martin & Harris Shortcomings

  • The company’s Cash Flow from Operations has been decreasing at a CAGR of -208.4 % from 2017 to 2020.
  • In the year 2020, the company has recorded negative growth of  4.6% in Profit after tax resulting in ₹ 69 Cr as against ₹ 72 Cr in FY20

Martin & Harris Opportunities

  • The COVID-19 pandemic had a moderate to high impact on the global clinical laboratory services market. 
  • Increasing cases of COVID-19 infected patients across the globe has led to a rise in clinical chemistry services, especially in the specialized chemistry testing segment. Laboratory testing and pharma demands have increased significantly and continue to grow at a staggering rate to keep pace with suspected cases of COVID-19, thus boosting the market revenue.

Martin & Harris Threats

  • Threats include several factors, such as new generic products that arrive in the market, new regulations, new trade barriers, changes to health insurance regulation, and even the lack of availability of qualified staff.
Martin & Harris Rating

  • RECOMMENDATION

    Strong Buy

  • Martin & Harris Detail Info

Industry Statistics

PRIVATE LIMITED

Registered In

India

last Updated

25/03/2021

Registered Date

22/07/1993

Stock Exchange Ticker

M&H

Reg Office: NH-8, Delhi Jaipur Highway, Village, Pachgaon (Fazalwas), Distt. Gurgaon, Haryana

Website: None

  • ROFR Required

Available in Depository

  • NSDL

  • CDSL

Available for Investment

  • Primary

  • Secondary

  • Investment Checklist

Management

Accounting Practice

Profitability

Solvency

Growth

Valuation